Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs Intravenous Ocrelizumab in Multiple Sclerosis
NCT05232825Phase 3Completed
- Sponsor
- Roche
- Start
- May 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Started May 2022; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05232825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232825.